防治新冠病毒化学药物专利合作网络演化研究

Study on the Evolution of Patent Cooperation Network of Chemical Drugs for Prevention and Treatment of COVID-19

摘要:

新冠肺炎疫情下,开展我国抗病毒化学药物的专利合作网络研究,对于增强我国抗病毒药物创新主体合作关系、拓宽研发知识流动和创新演化规律的认知有重要意义。对江苏信息中心“新冠疫情专利信息平台”数据库中的专利分别进行整体结构、个体结构、药物维度和省市合作分析,主要发现如下：(1)我国防治新冠病毒化学药物专利合作网络规模、合作关系和合作次数一直在增加,但合作密度有所下降,该领域中各创新主体之间还存在着较大合作空间；(2)专利合作网络关键节点如大学、研究机构或企业等在不同阶段变动比较大,说明主体很难建立长期稳定的合作关系；(3)防治不同类型病毒的化学药物专利合作网络规模和网络密度演化情况有所不同,这与病毒的特性有关；(4)从我国省市合作中心来说,出现了从北京为核心逐步向长三角、珠三角的核心省市合作转移的情形。

Abstract:

The paper studied cooperative patent network of antiviral drugs for COVID-19 in China with the context of epidemic situation. It would enhance the cooperation of antiviral agents in China and expand the recognition of R D knowledge flow and innovation rules of Chinese antiviral agents. It studied the overall structure, individual structure, drug dimension and cooperation between provinces and cities, based on the database of "COVID-19 patent information platform" of Jiangsu information center. The main findings are as follows: (1) The scale, cooperation and cooperation frequency of COVID-19 related antiviral drug cooperation network have been increasing, but the density of cooperation has been decreasing. The trend shows that there is still a large space for cooperation among innovation subjects in this field; (2) Most of the key nodes such as universities, research institutions or enterprises, have great variation in patent cooperation network, which shows that there are difficulties to establish long-term and stable cooperation relationship among innovation subjects; (3) The patent cooperation network scale and network density of antiviral drugs have changed differently, which depends on the characteristics of the diseases; (4) From the perspective of cooperation center between provinces and cities in China, there is an evolving tendency from Beijing to the cooperation among the core provinces and cities in the Delta and the Pearl River Delta.